Tazverik is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat follicular lymphoma in adults and children 16 years and older whose tumors are positive for the EZH2 mutation and who have received two previous therapies. Tazverik may be also referred to by its drug name, tazemetostat.
Tazverik is a methyltransferase inhibitor. Tazverik is believed to work by blocking the EZH2, which may prevent cancer cells from growing.
How do I take it?
Tazverik is generally taken orally twice a day.
Tazverik comes in the form of a tablet.
The FDA-approved label for Tazverik lists common side effects including pain, fatigue, nausea, abdominal pain, cough, and upper respiratory tract infections.
Rare but serious side effects listed for Tazverik include developing secondary cancers. Speak to your doctor if you experience bone pain, unusual tiredness, or low blood cell counts.
For more details about this treatment, visit:
Tazverik — Epizyme
Tazverik — RxList